## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -7.3% below STRENGTH zone (3.0-6.0%); PEG 1.01 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($297.67)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Has the Market Fully Priced In Amgen’s Rally After Pipeline and Regulatory Milestones?**
- Source: Simply Wall Street | 20251207T030903 | Somewhat-Bullish | Relevance: 100%
-  Amgen's stock has seen significant gains, up 27.2% year to date, fueled by an expanding pipeline and regulatory milestones. Analysis using Discounted Cash Flow and Price vs. Earnings models suggests Amgen is currently undervalued. The article presents bullish and bearish narratives for Amgen, with fair value estimates ranging from $322.88 to $404.87 per share.

**2. Who Owns Amgen? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20251209T130753 | Bullish | Relevance: 100%
-  This article details the top shareholders of Amgen Inc. (NASDAQ: AMGN), primarily large institutional investors and passive funds, alongside recent adjustments by active managers and hedge funds. It also reviews recent insider trading activity, noting that sales were modest and purchases by directors appeared administrative, suggesting a neutral stance on near-term performance. The overall sentiment indicates strong long-term confidence in Amgen's cash flow durability and pipeline potential.

**3. Amgen Raises Quarterly Dividend to $2.52 a Share From $2.38, Payable March 6 to Shareholders of Record as of Feb. 13**
- Source: marketscreener.com | 20251209T210752 | Bullish | Relevance: 99%
- Amgen Inc. has announced an increase in its quarterly dividend to $2.52 per share, up from $2.38 per share. This dividend is scheduled to be paid on March 6, 2026, to shareholders of record as of February 13, 2026. The increase signifies an approximate 5.9% boost in the company's dividend per share.

**4. Fayez Sarofim & Co Acquires 18,213 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20251209T103852 | Bullish | Relevance: 99%
-  Fayez Sarofim & Co has increased its stake in Amgen Inc. by 53.7%, purchasing an additional 18,213 shares in Q2, bringing their total holdings to 52,146 shares valued at $14.56 million. Amgen reported strong Q2 earnings, beating analyst estimates for EPS and revenue, and declared a quarterly dividend of $2.38 per share. Analysts generally maintain a "Moderate Buy" rating for Amgen, despite recent insider share sales.

**5. Amgen Inc. $AMGN Shares Sold by California Public Employees Retirement System**
- Source: MarketBeat | 20251207T090937 | Bullish | Relevance: 99%
-  California Public Employees Retirement System reduced its stake in Amgen Inc. by 0.4%, selling 9,206 shares. Despite this, Amgen (NASDAQ:AMGN) reported strong Q2 earnings, beating analyst expectations for both EPS and revenue, and announced a quarterly dividend of $2.38 per share. Several other institutional investors adjusted their positions in Amgen, and Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $335.65 for the stock.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |
| 2025-11-14 | Piper Sandler | $381 | $342 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | BMO Capital | main | Outperform |
| 2025-11-14 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-6.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Forward P/E 14.4x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +11%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $169.0B |
| Beta | 0.45 |
| 52W Range | $253.30 - $346.38 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 14.4 |
| Current P/E | 14.8 |
| YoY Growth | 2.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.5% to -7.3% (-6.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.3pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.06x) but short-term weakness (below SMA20). MACD histogram bearish (-4.20), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -7.26% (CS: 2) | Weak |
| RSI_14 | 39.7 | Neutral |
| MACD Histogram | -4.20 | Bearish |
| vs SMA20 | 0.931x | Below |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 1.057x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $313.85
- **Stop Loss:** $297.67 (5.2% risk)
- **Target:** $330.03 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 18
- **Position Value:** $5,649.30
- **Portfolio %:** 5.65%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*